Isolation and characterization of a CD34\(^+\) sub-clone in B-cell lymphoma

Ayad M. Al-Katib\(^1\), Abdul Shukkur Ebrahim\(^1\), Mustapha Kandouz\(^2\), Feras Zaiem\(^2\), Ali Raufi\(^1\), Salah Ebrahim\(^2\), Anwar Mohamed\(^2\), Nada Emara\(^1\) and Ali M. Gabali\(^2\)

\(^1\)Lymphoma Research Laboratory, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA
\(^2\)Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA

Correspondence to: Ayad M. Al-Katib, email: aa1526@wayne.edu

Keywords: CD34; B-cell non-Hodgkin’s lymphoma; minimal residual disease; lymphoma stem cell

Received: July 26, 2019  Accepted: December 02, 2019  Published: January 14, 2020

ABSTRACT

Non-Hodgkin’s lymphoma (NHL) is the most common hematological malignancy in the US. Many types remain incurable despite response to initial therapy and achievement of complete remission (CR). Advanced laboratory techniques like multicolor flow cytometry (FCM) and polymerase chain reaction (PCR) have demonstrated persistence of rare malignant cell population post therapy. However, the functional and biological characteristics of this population have not been elucidated.

Established B-lymphoma cell lines (B-NHL) and patient-derived samples (PDS) were analyzed using 8-color FCM. CD34\(^+\) sub-population was enriched using \textit{in vitro} exposure to 2-chlorodeoxyadenosine (2-CdA) and by CD34 magnetic beads. Genetic analysis of cell fractions was done by karyotyping and array comparative genomic hybridization (aCGH). Sensitivity to chemotherapy was assayed by short-term \textit{in vitro} exposure to chemotherapy. Clonogenicity was determined by soft agar colony formation assay, and proliferation was determined using DNA staining with propidium iodide and FCM.

FCM demonstrated the presence of a minute sub-clone of monotypic B-cells that express CD34 in B-NHL cell lines (3 of 3) and in PDS (8 of 8). This sub-population enriched up to 50 fold \textit{in vitro} by exposure to 2-CdA and up to 80% purity by CD34 magnetic bead column isolation. Except for CD34 expression, this population expressed identical phenotype and genotype to parent cells, but was more proliferative, Hoechst 33342-positive, clonogenic, and resistant to chemotherapy compared with the CD34\(^-\) population.

The isolated CD34\(^+\) monotypic B-cells may contribute to resistance of certain NHL to treatment and should be targeted by potential new drugs for NHL.

INTRODUCTION

Non-Hodgkin’s lymphoma (NHL) is the 7th most common cancer in the United States. More than 74,000 cases were diagnosed in the US in 2018 and almost 20,000 were expected to succumb to the disease [1]. NHL is comprised of a growing list of more than 100 entities based on pathologic, clinical and genetic features [2]. The natural history of NHL is quite variable with some types being slow growing ‘indolent’ (~40%) while others are aggressive or very aggressive [3, 4]. Ironically, the slow growing NHLs remain incurable whereas the aggressive types are curable although 20–40% of those will relapse and may become incurable [5]. All types of NHL are usually responsive to initial treatment and often achieve complete remission (CR), which is a prerequisite to cure. CR is defined as disappearance of lymphoma-related lesions as detected by clinical examination or state-of-the-art imaging techniques like PET/CT [6, 7]. Despite achievement of CR, all indolent NHLs and some aggressive ones relapse.
Recurrence of disease is believed to be due to persistence of a relatively small number of lymphoma cells that are below detection level of clinically employed response-evaluation methods. This notion is supported by observations that newer, more sensitive techniques like multicolor flow cytometry (FCM) or polymerase chain reaction (PCR) are able to detect such residual cell population (referred to as minimal residual disease [MRD]) in some NHL patients who are otherwise in CR post completion of therapy [8, 9]. MRD cells carry the same phenotypic and genetic markers as the original lymphoma as detected by FCM and PCR. What makes these cells resist therapy and survive, and how they are different from the rest of lymphoma cells is largely unknown. A study of preclinical mouse model mimicking MRD cells and relapse in acute lymphoblastic leukemia (ALL) patients suggested that drug resistance and dormancy might be linked and represent an acquired stem-like phenotype [10]. Yet, answering such questions may yield insight into developing more effective therapy for NHL. However, the study of MRD in lymphoma has been hampered by cost and lack of MRD monitoring in most prospective clinical trials of NHL [11]. It is encouraging that some of the ongoing clinical trials like the FOLL12 (EudraCT #2012-003170-60) and MIRO trial, EudraCT #2012-001676) have incorporated MRD evaluation.

In this study, we identified a minor cell population within clonal B-cells of lymphoma that expresses CD34 with unique features, including resistance to chemotherapy that distinguishes them from the rest of lymphoma cells. This report describes the isolation process and characterization of this sub-clone.

### RESULTS

#### Isolation of CD34⁺ cells

Flow cytometric analysis of all 3 B-lymphoma cell lines revealed the presence of a minor CD34⁺ population. Proportion of these cells was constant during the test period of 72 hours and was <1% (Table 1, Control columns). However this population was enriched several folds after treating cell cultures with 2CdA and progressively increased during the 72 hours of test period. Enrichment was highest in the follicular lymphoma cell line, WSU-FSCCL reaching more than 50 folds at 72 hours compared with control (13.2% vs 0.26%, Table 1), followed by WSU-WM, 10 fold, (2.36% vs 0.23%) and least in the aggressive diffuse large B-cell lymphoma cell line, WSU-DLCL2 (1.25% vs 0.71%).

To enrich the CD34⁺ population further, we applied a CD34 Microbead positive selection technique to 2CdA-treated WSU-WM cell line. As shown in Figure 1, a CD34⁺ cell fraction was enriched up to 80% purity using this method (Figure 1D). Western blots confirmed the higher expression of CD34 protein in the enriched population. These results confirmed the presence of CD34⁺ subpopulation within monotypic B-lymphoma cells and allowed the generation of large number of CD34⁺ cells for further analysis.

### Characterization of CD34⁺ cells

#### Phenotyping

We compared the phenotype of CD34 Microbead-isolated fraction from WSU-WM with parent cells. Except for CD34 expression, the Microbead-isolated cells exhibited identical phenotype to parent cells as demonstrated by 8-color flow cytometric analysis (Figure 2). Both fractions were clonal B-cells positive for CD10, CD19, CD20 and lambda light chain. This study shows that a subset of mature clonal B-cells can express CD34.

#### Karyotyping and comparative genomic hybridization (CGH) analysis

CD34⁺ cells isolated from WSU-WM also exhibited identical karyotype, SNP, and CGH profile to parent WSU-WM cells (Supplementary Figure 1). By karyotype, WSU-WM-CD34⁺ cells contained 46 chromosomes and exhibited 2p-, t (8;14)(q24; q32), and t (2;17)(q24; q21) translocations as clonal abnormalities (Supplementary Figure 1B). These results were the same as those of parent cells (Supplementary Figure 1A) and as reported in the original characterization of this cell line [12]. Targeted genome SNP profile of WSU-WM-CD34⁺ cells (Supplementary Figure 1C) showed identical pattern of absence of heterozygosity (AOH) as parent cells (Figure 1D). Similarly, whole genome copy number variant (CNV) showed fairly conserved profile of CD34⁺ and parent cells (Supplementary Figure 1E, 1F). Collectively, the findings

---

**Table 1: Expression of CD34 in human lymphoma cell lines**

|                  | WSU-WM | WSU-FSCCL | WSU-DLCL2 |
|------------------|--------|-----------|-----------|
|                  | Control| 2-CdA     | Control   | 2-CdA     | Control   | 2-CdA     |
| **24 h**         | 0.29   | 0.55      | 0.21      | 0.55      | 0.69      | 0.86      |
| **48 h**         | 0.14   | 1.01      | 0.2       | 1.43      | 0.45      | 0.51      |
| **72 h**         | 0.23   | 2.36      | 0.26      | 13.2      | 0.71      | 1.25      |

WSU-WM, WSU-FSCCL, WSU-DLCL2 are human lymphoma cell lines; 24 h, 48 h, 72 h indicate time in culture.
are indicative of same genetic composition of both cell populations.

**Hoechst 33342-stained side population (SP) analysis**

FACS analysis of different WSU-WM cell fractions after staining with Hoechst 33342 revealed that only few cells in parent and CD34- fractions were positive (Figure 3A, 3B). In contrast, SP was enriched in the CD34+ fraction (Figure 3C). The average number of SP cells in 3 independent experiments was ~40% in the CD34+ fraction of WSU-WM (Figure 3D).

**Growth pattern and clonogenicity of WSU-WM CD34+ cells**

Using StemPro media, CD34+ WSU-WM fractions showed more sustained viability in culture over 9 day

---

**Figure 1: FACS analysis of WSU-WM using CD34 magnetic beads isolation.** CD34+ subset cells were isolated from human WSU-WM cell line using CD34 Microbeads. Cells were stained with phycoerythrin (PE)-conjugated anti-CD34 antibody (PE-A). (A–C) Events are displayed as PE-A vs FSC-A to select singlets. A minor population of CD34+ cells was seen in the WSU-WM parent and WSU-WM-CD34- cells (A, B). The CD34+ subset population was enriched in the WSU-WM-CD34+ cells after bead separation (C). (D) Enrichment in WSU-WM-CD34+ cells was around (80%). All values represent mean ± SE of five independent experiments. ****P < 0.0001 by ANOVA for D. (E) Representative Western blots demonstrating CD34+ protein expression was increased in WSU-WM-CD34+ cell lysates compared with WSU-WM parent cells; an H-140 antibody clone was used to detect CD34; β-actin was used as a loading control.
period compared with parent cells (Figure 4A). Moreover, CD34+ cells exhibited different growth pattern compared with parent cells. The growth curves separated after the 4th day where the CD34+ cells demonstrated continued increase in cell number whereas parent cells were decreasing in number. Cell cycle analysis of the two cell subsets supported the growth pattern in cell culture. CD34+ cells exhibited higher percentage of cells in S phase compared with parent cells (Figure 4B–4D). Moreover, CD34+ cells were more clonogenic even in presence of chemotherapy agents, 2-CdA and doxorubicin compared with parent cells (Figure 4E) and demonstrated resistance to cell kill by these agents in liquid culture (Figure 4F). Expression of CD34+ cells decreased with time and was ~2% on day 9 of culture in the StemPro media.

Detection of CD34+ cells in patient-derived samples

Eight patient-derived samples were included in this study. The cases were selected retrospectively from the clinical laboratory data based on the following criteria: 1) A final diagnosis of mature B-cell malignancy, 2) Involvement of blood by the malignant process, 3) Inclusion of CD34 antibody in the staining panel. Patient data is summarized in Table 2 and details of 8-color flow cytometry data of the first 6 cases is shown in Supplementary Figure 2. Two of the cases (#1 and #6) had a clear diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Case #1 had stage 0 disease by Rai classification and case #6 had stage I. One case (#2) had Richter’s transformation and high WBC count (163.2 x 10^3/µL) and one (#8) had a diffuse large B cell lymphoma. Both of these cases had advanced stage disease (stage IV) by virtue of involving the blood. The remaining four cases were diagnosed as B-cell lymphoproliferative disorder (B-cell LPD) without further characterization.

CD34 expression was determined specifically on the clonal B-cells (Supplementary Figure 2) and ranged between 0.01% and 5.35%. Given the small number of cases, no conclusion can be drawn regarding factors that influence CD34 expression level. However, the highest expression (5.35%) was seen in the case of Richter’s syndrome. Overall, the patient-derived data lend support to, and was consistent with the cell line data.

DISCUSSION

In this report, we provide evidence for the existence of a minor subpopulation within mature malignant B-cells that expresses different features from the rest of cells. This population appears to have the same genetic composition, as determined by karyotype and CGH, and to express the same phenotype as the rest of cells. However, they exhibit distinct characteristics giving them potential important role in resistance to chemotherapy and incurability of disease. The distinguishing phenotypic marker of this subpopulation is expression of CD34. This CD34+ clonal B-cell subpopulation was identified in established B-cell lymphoma cell lines (3 of 3) (Table 1) and in all patient-derived samples (8 of 8) (Table 2).

Although CD34 is considered a marker of normal hematopoietic stem cells and for some acute myeloid leukemia, its expression is not limited to such cells. CD34 expression on non-myeloid, malignant hematopoietic cells was reported before. For example, CD34 was shown to be expressed in 24/45 of adult acute lymphoblastic leukemia (ALL) and was associated with Pgp-MDR1 phenotype and worse outcome compared with 21/45 CD34 negative cases

![Figure 2: Phenotypic characterization of WSU-WM-CD34+ subset cells.](image-url) Eight color multi parameter flow cytometric analysis of the surface antigen profiles of B-cell markers. (A–E), WSU-WM-Parent cells: CD20, CD10, CD19, and Lambda light chain were positive. (F–J): CD34 Magnetic bead-isolated cells were positive for CD20, CD10, CD19, Lambda and CD34.
Figure 3: Detection of a side population (SP) in WSU-WM. FACS analysis after Hoechst33342 loading reveals that a few of the SP cells were observed in the parent and CD34- cells (A, B), but this population was enriched in the WSU-WM-CD34+ cells (C). The percentage of SP cells in WSU-WM-CD34+ was around 40% (D). Analysis of representative results from three sets of independent experiments is shown. **P < 0.001 by ANOVA.
Only 11/24 (45%) of CD34 positive cases achieved CR after induction chemotherapy compared with 20/21 (95%) of CD34 negative cases. Survival was significantly shorter (6.6m vs 13.5m). A recent study highlights the importance of using multiple markers to detect MRD in B lymphoblastic leukemia [20]. Two case control studies of B-ALL patients and control participations at diagnosis and after 2–3 weeks of induction chemotherapy suggested that CD34/CD123 [21] and CD10/CD19/CD34 with CD45 or CD97 [22] are more specific for MRD detection in B-ALL. In another study, clonal CD34+CD19+ progenitors were detected in bone marrow of BCL2-IgH-positive follicular lymphoma patients [23]. Our study shows that such cells (CD34+CD19+) are not limited to follicular lymphoma since we were able to detect them in diffuse large B-cell lymphoma (WSU-DLCL2), Waldenström’s macroglobulinemia (WSU-WM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell lymphoproliferative disorders (fresh patient-derived samples).

CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that is expressed on early hematopoietic and vascular-associated tissue [24]. Its function overlaps with other CD34-related proteins, podocalyxin and endoglycan [25, 26]. These related proteins are also expressed on early hematopoietic progenitor cells. However, how these related molecules contribute to progenitor and stem cell function and behavior needs further investigation [27].

Clinically, CD34 is not considered part of the diagnostic antibody panel for lymphoma. Therefore, studies addressing minimal residual disease (MRD)
Table 2: CD34 expression in patient-derived blood samples

| Patient# | Diagnosis | Positive Immunophenotype | Karyotype/FISH | WBC/ALC | CD34% |
|----------|-----------|--------------------------|----------------|---------|-------|
| #1       | CLL/SLL   | CD5, CD11c, CD19, CD20, CD23, CD25, CD45, lambda | Deleted 13q14 | 24.1 × 10^3/ul | 0.01% |
| #2       | Richter’s syndrome | CD5, CD11c, CD19, CD20, CD23, CD25, CD45, kappa | N/A | 163.2 × 10^3/ul | 5.35% |
| #3       | B-Cell LPD | CD19, CD20, CD23, CD45, FMC7, kappa | Deleted 13q14 Deleted TP53/17p13 | 12 × 10^3/ul 4.3 × 10^3/ul | 0.19% |
| #4       | B-Cell LPD | CD5, CD19, CD20, CD23, CD45, FMC7, kappa | Deleted TP53/17p13 | N/A | 1.72% |
| #5       | B-Cell LPD | CD5, CD11c, CD19, CD20, CD23, CD45, kappa | N/A | N/A | 0.35% |
| #6       | CLL/SLL   | CD5, CD11c, CD19, CD20, CD23, CD38, CD45, kappa | Trisomy 12 | 20.9 × 10^3/ul 19 × 10^3/ul | 0.01% |
| #7       | B-Cell LPD | CD5, CD11c, CD19, CD22, CD38, FMC7, HLA-DR, kappa | Deleted 13q14 Deleted TP53/17p13 | 21.1 × 10^3/ul 4.1 × 10^3/ul | 0.02% |
| #8       | DLBCL     | CD5, CD10, CD11c, CD19, CD20, CD38, CD79a, FMC7, HLA-DR, kappa | N/A | 47.5 × 10^3/ul 10.4 × 10^3/ul | 0.25% |

Abbreviations: B-Cell LPD, B-cell lymphoproliferative disorder; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B cell lymphoma; F, female; M, male; N/A, not available; WBC/ALC, white blood cell count/absolute lymphocyte count.

in lymphoma do not determine if there is differential expression of this marker in MRD cell population [28, 29]. Another technique for detection of MRD in lymphoma is based on PCR for known chromosomal translocations like the t (11;14), t (14;18) or immunoglobulin heavy chain genes (IgH) [30, 31]. Newer molecular technologies such as droplet digital PCR and next generation sequencing have also been described for monitoring MRD in B cells lymphoproliferative disease [32]. PCR technique, like the flow cytometry will not detect the CD34+ population within MRD since CD34+ cells have the same genetic composition as parent cells, at least by karyotype and CGH analyses (Supplementary Figure 1). We hypothesize that CD34+ cells are epigenetically modified in order to respond and adapt to external signals. Comprehensive gene sequencing efforts in follicular lymphoma, for example, lends support to our hypothesis. A study by Okosun et al. [33] demonstrated recurrent mutations in linker histones, and chromatin regulators (CREBBP, EZH2, and MLL2) as early driver genes occurring in a common progenitor clone (CPC). The authors concluded that the mutational landscape of follicular lymphoma is predominantly epigenetic. However, it is possible that CD34+ cells do have genetic aberrations not detectable by karyotype or CGH given the limitations of these techniques [34].

In order to obtain large number of CD34+ cells and characterize this cell population further, we sought to enrich the CD34+ population in our cell lines using 2 strategies, 2-CdA and CD34 magnetic beads separation. Our initial enrichment step using in vitro exposure to the chemotherapy agent 2-CdA simulates clinical MRD setting. Such strategy showed up to 50 fold enrichment of the CD34+ population (Table 1) suggesting that MRD cells in clinical studies are likely to preferentially express CD34. We believe that adding CD34 to MRD antibody panel in clinical studies of B-cell lymphoma will be useful in capturing this population. It should be emphasized, however, that our study is performed in established cell lines and in patient-derived samples of limited number. Therefore, larger prospective study of patient-derived samples is needed to establish the presence of CD34+ cell fraction in MRD samples at diagnosis and after successful treatment.

The mechanism of 2-CdA-induced CD34+ cell enhancement is not clear. However, we postulate that 2-CdA induced preferential killing of CD34 negative cells leading to a relative increase in CD34+ cells. This postulation is based on the hypothesis that CD34+ are more resistant to chemotherapy as part of their ‘stem cell’ characteristics. Our experimental data showed good inverse correlation between cytotoxicity and CD34+ cells after exposure to chemotherapy in vitro. In one experiment, exposure of WSU-WM cells to 2-CdA for 72 hours resulted in 5.7 fold reduction in cell viability and a 5.9 fold increase in the percentage of CD34+ cells (data not shown).

Although the CD34+ population has identical phenotype, except for CD34 expression, and genetic composition to parent cells, they exhibited important differences in some of their characteristics and biological
behavior. Some of these features are similar to those described for tumor initiating cells. For example, 43% of the CD34+ cells in our WSU-WM cells were also Hoechst 33342+ (Figure 3). This sub-population, also known as side population (SP), was described before in different human solid tumors [35] and in leukemia [36]. It was shown to initiate tumors in mouse cell lines [37]. SP cells also demonstrated resistance to chemotherapy in Hodgkin lymphoma but, interestingly, were susceptible to elimination by novel therapies like immunotherapy [38] and NF-kB inhibition [39]. Consistent with these observations, we have reported earlier that a novel experimental therapeutic agent, SAR3419 (a CD19 antibody-drug conjugate) was far more effective against our WSU-FSCCL and WSU-DLCL2 xenograft models than standard chemotherapy regimen, CHOP or rituximab [16]. It is possible, although not proven, that such enhanced activity is due to targeting the CD34+ population –demonstrated in both of these models- which are also CD19+.

Other features of the CD34+ sub-population isolated in our studies are enhanced survival, clonogenicity and proliferation and resistance to chemotherapy in vitro (Figure 4). Although it is commonly believed that stem cells are usually quiescent, there is evidence that some tumor initiating cells are proliferative [40]. Enhanced cell survival in culture media that supports stem cells (StemPro®) (Figure 4A) and in presence of chemotherapy agents (Figure 4F) as well as clonogenicity in presence of chemotherapy agents (Figure 4E) are all indications of a unique cell population that is likely to be clinically significant.

Collectively, our results indicate that the sub-population of CD34+ clonotypic B-cells that we isolated is a candidate lymphoma stem cell (LSC). The concept of LSC is not new [41, 42]. However, definitive evidence for its existence has not been provided. Part of the difficulty is the definition of LSC, or cancer stem cell in general. It is also not clear if LSC is a fixed cell type or represent multiple compartments. Our finding that only a subset of CD34+ cells is SP+ suggests heterogeneity within the CD34+ population. Such model allows LSC to adapt to external environment by switching between proliferative and survival mode in order to evade therapy. It is imperative, therefore that future drug development in lymphoma focus on this cell population as target. Ability to isolate and enrich such cells from established cell lines as we did provides a mechanism for testing experimental therapeutic agents against these cells.

**MATERIALS AND METHODS**

**Cell culture**

Three human B-lymphoma cell lines were used in this study, WSU-WM [12], WSU-FSCCL [13], and WSU-DLCL2 [14]. The WSU-WM cell line is an IgM-secreting lymphoplasmacytic lymphoma established from a patient with Waldenström’s macroglobulinemia (WM). The WSU-FSCCL cell line was established from a patient with follicular small cleaved cell lymphoma (FSCCL) which is equivalent to follicular lymphoma, grade 1 by WHO classification [15]. The WSU-DLCL2 represents an aggressive diffuse large cell lymphoma (DLCL). All cell lines were established by the Lymphoma Research Laboratory at Wayne State University (WSU), Epstein-Barr virus (EBV)-negative, well characterized and authenticated. Cells are maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and antibiotics as previously described [16]. CD34+ cells were also cultured in StemPro®-34 SFM medium. This is a serum-free medium (SFM) containing StemPro®-34 nutrient supplement (Gibco by Life Technologies) specifically formulated to support the development of human hematopoietic cells in culture.

**Patient-derived samples**

Blood specimens analyzed in the clinical laboratory for suspected diagnosis of hematopoietic malignancy and worked up for both leukemia and lymphoma diagnosis were reviewed. Cases that had final diagnosis of a B-cell malignant process, and had CD34 marker included in the antibody panel were included in this study. Final diagnosis was confirmed by expert Hematopathologist, (AG). An 8-color flow cytometry using a FACS Canto II from Becton Dickinson (San Jose, CA, USA) was conducted on these blood samples. Both leukemia and lymphoma staining protocols (Supplementary Table 1) as described below were applied since the diagnosis was not clear at the time of testing.

**Surface phenotyping**

Three and 8 color flow cytometry analysis was conducted on cell lines and patient-derived samples to confirm B-cell clonality, and to identify and characterize CD34+ cells. Cultured cells were collected from the media by centrifugation in 15 ml tube for 15 minutes at 300 g at room temperature. Cell pellets were washed using phosphate-buffered saline (PBS) and then suspended in PBS with 30% heat inactivated Adult Bovine Serum (ABS) (Atlanta Biologicals Inc.; Flowery Branch, GA, USA) to block non-specific binding. After performing cell counts and viability, as described below, cells were centrifuged and the pellets were incubated with CD19-FITC, CD10-PE, and CD34-PC5, or Isotype controls (Beckman Coulter Inc.; Brea, CA) using manufacturer recommended volumes and incubation conditions. Cells were washed briefly in PBS and the pellets were suspended and fixed in 0.4 ml of 0.4% formaldehyde-PBS.
solution (Polysciences Inc.; Warrington, PA, USA) prior to flow cytometry event acquisition using Coulter flow cytometer (Beckman Coulter Inc.; Brea, CA, USA). The fluorescence intensity of CD19, CD10 and CD34 antigens of 10,000 cells were analyzed after gating on intact cells using forward and light-scatter patterns. Boolean gating strategies were employed to gate the CD34 positive and CD34 negative fractions, which were then analyzed for CD19 and CD10 expression.

For patient-derived specimens, an 8-color flow cytometry using a FACS Canto II from Becton and Dickinson (BD; San Jose, CA, USA) was used. A lymphoma and acute leukemia staining protocols were applied to peripheral blood samples using 8-color antibody panels as shown in Supplementary Table 1. In contrast to the leukemia staining protocol, the lymphoma protocol is preceded by two steps that include a prewash to remove excess specimen immunoglobulin that may interfere with the monoclonal antibodies and incubation with normal rabbit serum (NRS) to neutralize non-specific binding sites on cell surface. Briefly, two washes are done by adding 15 ml of wash media (0.9% NaCl, 0.1% Na-azide and 10% Heat inactivated fetal calf serum, HI-FCS) to 300 µl of whole blood, centrifuged at 300 × g, at room temperature, for 3 minutes and decant thoroughly. After the second decant, 1 ml of NRS is added to the cell pellet, mixed gently, and incubated at 37°C for 30 minutes. After incubation, cells are washed and resuspended in up to 500 µl of RPMI containing 5% HI-FCS. After these two steps, the lymphoma and leukemia staining protocols are similar. Briefly, 100 µl of whole blood obtained from individuals with non-Hodgkin’s B-cell lymphoma patients were incubated with the appropriate antibodies for 10 minutes at 4°C in the dark. Cells were further processed using a standard lysed whole blood procedure by adding 2 ml FACS lysing solution (BD, San Jose, CA, USA), vortexed gently, and then incubated in the dark for 10 min at room temperature. The cells were centrifuged at 300 × g for 5 minutes at room temperature, washed twice in wash media and the pellets resuspended in 0.5 ml of wash media and the analyzed within 4 hours. In general, a minimum of 10,000 events/cells was acquired.

2-Chlorodeoxyadenosine (2-CdA) treatment

6 × 10⁶ cells of WSU-WM, WSU-FSCCL, and WSU-DLCL2 in 5 mL culture media were exposed to 100 nM concentration of 2-CdA or PBS (control) for up to 72 hours. Cell count and viability was determined every 24 hours as described below. Simultaneously, 3 color flow cytometry was conducted at each time point as described above to enumerate CD34⁺ cells.

CD34 magnetic bead isolation

10⁶ cells of WSU-WM cells in T-75 tissue culture flasks were exposed to 2-CdA at 100 nM for 48 hours and cell count and viability are determined. Cells were then processed for the isolation of CD34⁺ cells using CD34 MicroBead Kit UltradePure (Miltenyi Biotech, Auburn, CA) following manufacturer protocol. Briefly, cells were incubated with 100 µL of CD34 MicroBeads for 30 minutes at 4°C, washed, resuspended in 500 µL buffer and applied onto MS column placed in magnetic field of MACS Separator. CD34⁺ cells are pulled towards the internal surface of the column through the iron magnetic beads attached to the CD34 antibody. The column is then rinsed 3 times with 500 µl of buffer to collect flowing through CD34-unlabeled cells. Column is then removed from the separator and CD34-labeled cells are pushed out using a plunger, resuspended in 1mL of buffer. Collected cell fractions are then stained with CD34PE (#130-081-002, Miltenyi Biotech) and analyzed by flow cytometry.

Soft agar colony formation assay

The colony formation assay was conducted to assess clonogenic potential of different cell fractions as described previously [12]. In brief, Control (WSU-WM parent cells), and CD34⁺ WSU-WM cells were treated with the cytotoxic drugs Doxorubicin (1.5 pM) and 2CdA (50 nM) for 48 hrs. Single cell suspensions in complete RPMI medium containing 0.35% noble agar (Difco, Maryland) were plated at a density of 5 × 10⁶ cells in six-well plates coated previously with 0.6% base agar and maintained at 37°C in a humidified atmosphere containing 5% CO2 for 14 days. Colonies >0.2 mm in diameter were counted in eight random fields and normalized to control cells.

Cell cycle analysis

Flow cytometric analysis of propidium iodide (PI)-stained cells was conducted to assess the cell cycle under different experimental conditions. WSU-WM-parent, -CD34⁺, and -CD34⁻ cells were collected and centrifuged twice in cold PBS. Cells were then fixed in 5 ml of 70% ethanol and stored at 4°C overnight [17]. Cells were centrifuged and resuspended in 1 ml of staining buffer containing 50 ug/ml propidium iodide, 100 µg/ml of RNase A, and 0.1% of Triton X-100. DNA content was analyzed on a Coulter EPICS 753 flow cytometer and different stages of the cell cycle were determined using a ModFit 5.2 computer program. The flow cytometry work was done at the Microscopy, Imaging and Cytometry Resources Core at Wayne State University.

Side population (SP) analysis

The fluorescent vital dye Hoechst 33342 binds DNA in living cells and was shown to stain hematopoietic cells that have stem cell characteristics [18]. We therefore sought to evaluate our CD34⁺ cell fraction for staining characteristics with this dye. WSU-WM cell suspensions
were labeled with Hoechst 33342 dye (Invitrogen by ThermoFisher Scientific). Briefly, cells were resuspended at 1 × 10⁶/mL in pre-warmed RPMI with 10% FBS medium. Hoechst 33342 dye was added at a final concentration of 5 μg/mL and the cells were incubated at 37°C for 90 min with intermittent shaking. At the end of the incubation, cells were washed with ice-cold PBS and analyzed on a Coulter EPICS 753 flow cytometer.

**Cell count and viability**

Cells were seeded at a density of 0.2 × 10⁶ viable cells/mL per well in a 24-well plate (Costar, Cambridge, MA, USA) for variable periods of time. The number of viable cells was determined by trypan blue exclusion (Sigma Chemical Co. St. Louis, MO, USA) at 24 hour intervals [17].

**Immunoblotting**

Cells were harvested, washed in PBS and lysed in M-PER lysis buffer containing a protease and phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL, USA) [17]. Equal amounts of protein lysates were subjected to SDS-PAGE followed by blotting with the indicated antibodies and detection by Western Super Signal West Pico Chemiluminescent substrate reagents (Thermo Scientific, Rockford, IL, USA). Images were quantified using ImageJ densitometry software (Version 1.45, US National Institutes of Health) and normalized to the actin signal used as internal control. Data are presented as relative band signal intensity compared to control.

**Cytogenetics**

WSU-WM and WSU-WM-CD34+ cells in log phase of growth were exposed to colcemid (0.05 pg/mL) for 1 hour. Cells were then harvested and treated with 0.075 mol/L potassium chloride for 15 minutes before they were fixed with 3:1 methanol:acetic acid.Slides were prepared by dropping cell suspension onto ethanol-cleaned glass microscope slides. Q and G-banding methods were applied in the staining of chromosomes. From each culture, 20 to 30 cells were analyzed microscopically and karyotypes prepared.

**Comparative genomic hybridization (Array-CGH)**

Chromosomal microarray (CMA) using the oligonucleotide-single nucleotide polymorphism (Oligo-SNP), whole genome Agilent 180K GGXChip+SNP (Agilent Technologies, Inc) was performed. The approximate distance between probes is 80kb with a distance of 20kb in targeted regions. Thresholds for the detection of deletions and duplications are 6 probes with an average value of .25 and .20 respectively. The test is useful for the detection of DNA copy number losses or gains associated with chromosomal imbalances at multiple targeted sites throughout the genome. In addition this test may detect copy neutral aberrations such as uniparental disomy (UPD) and absence of heterozygosity (AOH). This array does not detect balanced reciprocal translocations, Robertsonian translocations, inversions, balanced insertions, point mutations, or imbalances of regions not represented on the microarray.

**Data analysis and statistics**

Statistics were conducted using GraphPad Prism 5.0 for Windows (GraphPad Software) and tests were done with one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001). P values less than 0.05 were considered to be statistically significant. Results are displayed as averages with error bars indicating standard deviations (SD). ImageJ densitometry software (Version 1.45, US National Institutes of Health) was used for quantification of Western blot bands. Selected bands were quantified based on their relative integrated intensities, calculated as the product of the selected pixel area and the mean gray value for those pixels normalized to the internal control.

**Author contributions**

Ayad Al-Katib: conception of study, supervision of the project, data analysis, and manuscript writing; Abdul Shukkur Ebrahim: Technical conduct of experiments, data generation and analysis, manuscript writing; Mustapha Kandouz: Discussion of experimental results, manuscript review and critique; Feras Zaiem: Provided patient-derived data; Ali Raufi: Conception of the project, literature search and data analysis: Salah Ebrahim: Analysis and interpretation of the comparative genomic hybridization (Array CGH) data; Anwar Mohamed: Analysis and interpretation of cytogenetic data; Nada Emara: Technical assistance with experiments; Ali Gabali: Analysis and interpretation of patient-derived data, discussion of the project, review of the manuscript.

**ACKNOWLEDGMENTS**

The authors wish to thank Eric Van Buren and Dr. Jessica Back at the Karmanos Cancer Institute Flow Cytometry Core Facility for running the flow cytometric experiments. We also wish to thank Steven Buck, Children’s Hospital of Michigan, Department of Hematology and Oncology for excellent flow cytometry support. The authors wish to acknowledge the Wayne and Joan Webber Foundation, and the Birdseye Fund for Lymphoma Research for financial support.
CONFLICTS OF INTEREST

The authors declare no potential conflicts of interest.

FUNDING

This work was supported by NIH grant # R21 CA238139. The Microscopy, Imaging and Cytometry Resources Core is supported, in part, by NIH Center grant P30CA022453 to The Karmanos Cancer Institute, Wayne State University, and the Perinatology Research Branch of the National Institutes of Child Health and Development, Wayne State University. The study was also supported by the Wayne and Joan Webber Foundation, and the Birdseye Fund for Lymphoma Research.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018; 68:7–30. [PubMed]
2. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117:5019–5032. [PubMed]
3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127:2375–2390. [PubMed]
4. Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program. 2011; 2011:506–514. [PubMed]
5. National Guideline Alliance (UK). Non-Hodgkin’s Lymphoma: Diagnosis and Management. London: National Institute for Health and Care Excellence (UK); 2016. (NICE Guideline, No. 52.) Available from: [PubMed]
6. Barrington SF, Mikhail NG, Kostakoglu L, Meigman M, Hutchings M, Müller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014; 32:3048–3058. [PubMed]
7. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphoma Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32:3059–3068. [PubMed]
8. Gritti G, Pavoni C, Rambaldi A. Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era? Mediterr J Hematol Infect Dis. 2017; 9:e2017010. [PubMed]
9. Hoster E, Pott C. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. Hematology Am Soc Hematol Educ Program. 2016; 2016:437–445. [PubMed]
10. Ebinger S, Özdemir EZ, Ziegenhain C, Tiedt S, Castro Alves C, Grunert M, Dworzak M, Lutz C, Turati VA, Enver T, Horny TP, Sotlar K, Parekh S, et al. Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia. Cancer Cell. 2016; 30:849–862. [PubMed]
11. Chase ML, Armand P. Minimal residual disease in non-Hodgkin lymphoma – current applications and future directions. Br J Haematol. 2018; 180:177–188. [PubMed]
12. al-Katib A, Mohammad R, Hamdan M, Mohamed AN, Dan M, Smith MR. Propagation of Waldenstrom’s macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood. 1993; 81:3034–3042. [PubMed]
13. Mohammed RM, Mohamed AN, Smith MR, Jawadi NS, al-Katib A. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet. 1993; 70:62–67. [PubMed]
14. Mohammed RM, Mohamed AN, Smith MR, Jawadi NS, al-Katib A. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet. 1993; 70:62–67. [PubMed]
15. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009; 2009:523–531. [PubMed]
16. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuañy-Amorín C. Superior antitumor activity of SAR3419...
to rituximab in xenograft models for non-Hodgkin’s lymphoma. Clin Cancer Res. 2009; 15:4038–4045. https://doi.org/10.1158/1078-0432.CCR-08-2808. [PubMed]

17. Ebrahim AS, Kandouz M, Liddane A, Sabbagh H, Hou Y, Li C, Al-Katib A. PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin’s lymphoma. Oncotarget. 2016; 7:42374–42384. https://doi.org/10.18632/oncotarget.9872. [PubMed]

18. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Identification of CD34 family of sialomucins in hematopoiesis. Immunol Rev. 2004; 193:179–1806. https://doi.org/10.1084/jem.183.4.1797. [PubMed]

19. Cacciola E, Guglielmo P, Cacciola E, Stagno F, Cacciola RR, Impera S. CD34 expression in adult acute lymphoblastic leukemia. Leuk Lymphoma. 1995; 18:31–36. https://doi.org/10.3109/10428199509075300. [PubMed]

20. Tsitsikov E, Harris MH, Silverman LB, Sallan SE, Weinberg RH. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia. J Immunol Methods. 2014; 406:131–136. https://doi.org/10.1016/j.jim.2014.03.004. [PubMed]

21. Zeidan MA, Kamal HM, El Shabrawy DA, Esh AM, Sattar RH. Detection of minimal residual disease in childhood B acute lymphoblastic leukemia by 4-color flowcytometry. Int J Lab Hematol. 2018; 40:343–351. https://doi.org/10.1111/ijlh.12795. [PubMed]

22. Baraka A, Sherief LM, Kamal NM, Shorbagy SE. Detection of minimal residual disease in childhood B acute lymphoblastic leukemia in children. Blood Cells Mol Dis. 2016; 59:113–118. https://doi.org/10.1016/j.bcmd.2016.05.005. [PubMed]

23. Macintyre EA, Belanger C, Debert C, Canioni D, Turhan AG, Azagury M, Hermine O, Varet B, Flandrin G, Schmitt S. Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. J Mol Diagn. 2015; 17:652–660. https://doi.org/10.1016/j.jmoldx.2015.05.007. [PubMed]

24. Davuluri Y, Cho-Vega JH, Singh RR, Ma S, Wang Y, Li C, Al-Katib A. PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin’s lymphoma. Oncotarget. 2016; 7:42374–42384. https://doi.org/10.18632/oncotarget.9872. [PubMed]

25. Soeren sen CD, Jorgensen EM, Nederby L, Hokland P, Nyvold CG. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas. J Immunol Methods. 2014; 406:131–136. https://doi.org/10.1016/j.jim.2014.03.004. [PubMed]

26. Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saracci E, Ghione P, Genuardi E, Barbero D, Omedè P, et al. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. J Mol Diagn. 2015; 17:652–660. https://doi.org/10.1016/j.jmoldx.2015.05.007. [PubMed]

27. Dogliotti I, Drandi D, Genuardi E, Ferrero S. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell lymphoid Malignancies. J Clin Med. 2018; 7:288. https://doi.org/10.3390/jcm7090288. [PubMed]

28. Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014; 46:176–181. https://doi.org/10.1038/ng.2856. [PubMed]

29. Seto M, Honma K, Nakagawa M. Diversity of genome profiles in malignant lymphoma. Cancer Sci. 2010; 101:573–578. https://doi.org/10.1111/j.1349-7006.2009.01452.x. [PubMed]

30. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtem JG, Jax C. Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. J Biol Chem. 2000; 275:9001–9010. https://doi.org/10.1074/jbc.275.12.9001. [PubMed]

31. Kerosuo L, Juvonen E, Alitalo R, Gylling M, Kerjaschki D, Miettinen A. Podocalyxin in human haematopoietic cells. Br J Haematol. 2004; 124:809–818. https://doi.org/10.1111/j.1365-2457.2004.04840.x. [PubMed]

32. Furness SG, McNagny K. Beyond mere markers: functions for CD34 family of sialomucins in hematopoiesis. Immunol Res. 2006; 34:13–32. https://doi.org/10.1385/IR:34:1:13. [PubMed]

33. Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res. 2014; 20:6398–6405. https://doi.org/10.1158/1078-0432.CCR-14-0407. [PubMed]

34. Cheminant M, Derriex C, Touzart A, Schmit S, Grenier A, Trieu Quang A, Delfau-Larue MH, Lhermitte L, Thiéblemont C, Ribrag V, Cheze S, Sanhes S, Jardin F, et al. Minimal residual disease monitoring by 8-color flow cytometry in manent cell lymphoma: an EU-MCL and LYSAL study. Haematologica. 2016; 101:336–345. https://doi.org/10.3324/haematol.2015.134957. [PubMed]

35. Summar L, Johnston D, Cloutier D, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014; 46:176–181. https://doi.org/10.1038/ng.2856. [PubMed]
38. Shafer JA, Cruz CR, Leen AM, Ku S, Lu A, Rousseau A, Heslop HE, Rooney CM, Bollard CM, Foster AE. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010; 51:870–880. [PubMed]

39. Nakashima M, Ishii Y, Watanabe M, Togano T, Umezawa K, Higashihara M, Watanabe T, Horie R. The side population, as a precursor of Hodgkin and Reed-Sternberg cells and a target for nuclear factor-kappaB inhibitors in Hodgkin’s lymphoma. Cancer Sci. 2010; 101:2490–2496. [PubMed]

40. Kuranda K, Berthon C, Dupont C, Wolowiec D, Leleu X, Polakowska R, Jouy N, Quesnel B. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients. Exp Hematol. 2010; 38:124–131. [PubMed]

41. Hart J, Turner AR, Larratt L, Russell J, Franko B, Frantz C, Paonessa T, Mansoor A, Lai R. Transmission of a follicular lymphoma by allogeneic bone marrow transplantation—evidence to support the existence of lymphoma progenitor cells. Br J Haematol. 2007; 136:166–167. [PubMed]

42. Martinez-Escala ME, Kuzel TM, Kaplan JB, Petrich A, Nardone B, Rosen ST, Guitart J. Durable responses with maintenance dose-sparing regimens of Romidepsin in cutaneous T-cell lymphoma. JAMA Oncol. 2016; 2:790. [PubMed]